نتایج جستجو برای: hiv 1 dna vaccine

تعداد نتایج: 3346593  

2014
Craig B. Wilen Robert W. Doms

For HIV to enter cells, the viral surface protein Envelope (Env) must sequentially bind the host protein CD4 and one of two coreceptors, either CCR5 or CXCR4. This triggers conformational changes in Env that result in fusion of the host and viral membranes. Our understanding of this process has led to the development of successful anti-viral drugs and provided insights into viral pathogenesis. ...

2011
Sandhya Vasan Arlene Hurley Sarah J. Schlesinger Drew Hannaman David F. Gardiner Daniel P. Dugin Mar Boente-Carrera Roselle Vittorino Marina Caskey Johanne Andersen Yaoxing Huang Josephine H. Cox Tony Tarragona-Fiol Dilbinder K. Gill Hannah Cheeseman Lorna Clark Len Dally Carol Smith Claudia Schmidt Harriet H. Park Jakub T. Kopycinski Jill Gilmour Patricia Fast Robert Bernard David D. Ho

BACKGROUND DNA-based vaccines have been safe but weakly immunogenic in humans to date. METHODS AND FINDINGS We sought to determine the safety, tolerability, and immunogenicity of ADVAX, a multigenic HIV-1 DNA vaccine candidate, injected intramuscularly by in vivo electroporation (EP) in a Phase-1, double-blind, randomized placebo-controlled trial in healthy volunteers. Eight volunteers each r...

Journal: :The Journal of Experimental Medicine 2006
Christine Trumpfheller Jennifer S. Finke Carolina B. López Thomas M. Moran Bruno Moltedo Helena Soares Yaoxing Huang Sarah J. Schlesinger Chae Gyu Park Michel C. Nussenzweig Angela Granelli-Piperno Ralph M. Steinman

Current human immunodeficiency virus (HIV) vaccine approaches emphasize prime boost strategies comprising multiple doses of DNA vaccine and recombinant viral vectors. We are developing a protein-based approach that directly harnesses principles for generating T cell immunity. Vaccine is delivered to maturing dendritic cells in lymphoid tissue by engineering protein antigen into an antibody to D...

Journal: Vaccine Research 2014
Alijan Tabarraie, Amir Ghaemi, Atefeh Saeedi, Malihe Naderi, Mishar Kelishdi,

Background: Hepatitis C (HCV) is a worldwide problem without an effective vaccine with more than 170 million chronically infected people worldwide. DNA vaccines expressing antigenic portions of the virus with adjutants have recently been developed as a novel vaccination technology. Objectives: In the present study, a DNA vaccine expressing HCV core protein was developed with IL12 as a genetic a...

Journal: :The Journal of Experimental Medicine 2008
Rafick-Pierre Sekaly

The world of human immunodeficiency virus (HIV) vaccines has suffered a baffling setback. The first trial of a vaccine designed to elicit strong cellular immunity has shown no protection against infection. More alarmingly, the vaccine appeared to increase the rate of HIV infection in individuals with prior immunity against the adenovirus vector used in the vaccine. A new study in this issue sug...

2015
Juliet Mpendo Gaudensia Mutua Julien Nyombayire Rosine Ingabire Annet Nanvubya Omu Anzala Etienne Karita Peter Hayes Jakub Kopycinski Len Dally Drew Hannaman Michael A. Egan John H. Eldridge Kristen Syvertsen Jennifer Lehrman Beth Rasmussen Jill Gilmour Josephine H. Cox Patricia E. Fast Claudia Schmidt Thomas L Richie

BACKGROUND Strategies to enhance the immunogenicity of DNA vaccines in humans include i) co-administration of molecular adjuvants, ii) intramuscular administration followed by in vivo electroporation (IM/EP) and/or iii) boosting with a different vaccine. Combining these strategies provided protection of macaques challenged with SIV; this clinical trial was designed to mimic the vaccine regimen ...

Journal: :Journal of immunology 2000
K Kusakabe K Q Xin H Katoh K Sumino E Hagiwara S Kawamoto K Okuda Y Miyagi I Aoki K Nishioka D Klinman

The mechanism of immune activation induced by a plasmid-encoding GM-CSF (pGM-CSF), administered in combination with a DNA vaccine encoding the envelope of HIV, was studied. Injecting pGM-CSF i.m. into mice 3 days before DNA vaccination primarily induced a Th2 response. Simultaneous administration of the DNA vaccine plus pGM-CSF activated both a Th1 and a Th2 response. When the plasmid was injec...

Journal: :Infection and immunity 2004
Steven C Derrick Charlene Repique Philip Snoy Amy Li Yang Sheldon Morris

Tuberculosis (TB) is the most common opportunistic disease and a potentially fatal complication among immunocompromised individuals infected with human immunodeficiency virus (HIV). Effective vaccination against TB in persons with HIV has been considered unlikely because of the central role that CD4 cells play in controlling tuberculous infections. Here we show that the vaccination of CD8(-/-) ...

2015
Hai-Bo Wang Qiu-Hua Mo Ze Yang

Human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) is a worldwide epidemic, with over 35 million people infected currently. Therefore, the development of a safe and effective HIV-1 vaccine is on top of the global health priority. In the past few years, there have been many promising advances in the prevention of HIV/AIDS, among which the RV144 Thai trial has been encour...

2016
So Youn Shin

Despite the tremendous efforts to develop a successful human immunodeficiency virus (HIV) vaccine, the quest for a safe and effective HIV vaccine seems to be remarkably long and winding. Disappointing results from previous clinical trials of VaxGen's AIDSVAXgp120 vaccine and MRKAd5 HIV-1 Gag/Pol/Nef vaccine emphasize that understanding the correlates of immune protection in HIV infection is the...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید